Cannabinoid with Irritable Bowel Syndrome

Overview

About this study

The purpose of this study is to evaluate the effectiveness of cannabis in reducing pain, discomfort, and nausea associated with irritable bowel syndrome (IBS) symptoms among diagnosed patients.

 

 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Participants will be patients diagnosed with constipation or non-constipation IBS [that is IBS-D (diarrhea), IBS-C (constipation) IBS-M (mixed), IBS-U (unspecified)] with chronic abdominal pain diagnosed in their medical record at Mayo Clinic with chronic pain documented for > 3 months;
  • Participants will be 18-70 years of age;
  • Participants will have cannabis use disorder;
  • Participants will be capable of providing informed consent and complete study tasks.

Exclusion Criteria: 

  • Alcohol or illicit substance dependence or abuse (other than cannabis) in the past 12 months.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/18/2024. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Houssam Halawi, M.D.

Open for enrollment

Contact information:

Ayah Matar M.D.

(507) 538-8083

Matar.Ayah@mayo.edu

More information

Publications

Publications are currently not available